NOVELTY NOBILITY Inc.

Learn More

Details: Fully human IgG1 monoclonal antibody discovered by Novelty Nobility

Science: Unlike most investigational retinal therapies which are currently participating in a race to increase the durability of anti-VEGF therapies, we focus on the fundamentals of the retinal diseases — hypoxia. Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor stabilized by hypoxia, playing a pivotal role in the onset and development of retinal diseases. Interestingly, our cKIT inhibitor NN2101 regulates HIF-1α and mediates vascular permeability, inducing vessel normalization and resolution of hypoxia. We dream of curing retinal diseases.

Publications

Learn More

Details: Novel antibody-drug conjugate (ADC) designed and created by Novelty Nobility- Fully human IgG1 monoclonal antibody discovered by Novelty Nobility conjugated with ThioBridge®, a proprietary site-specific ADC cleavable linker technology of Abzena, and MMAE with DAR 4

Science: Developed to treat both cKIT wildtype and activating mutation-driven cancers, NN3201 monotherapy exhibited complete remission in all tested xenograft model studies of hard-to-treat cancers such as SCLC and AML. This novel ADC is powered by dual modalities that simultaneously address the tumor microenvironment (TME) via cKIT pathway inhibition and by targeting cKIT positive tumors for ADC internalization. NN3201 also demonstrates a superior preclinical safety profile with a large therapeutic index.

Publications

Learn More

Science: An undruggable target from a traditional antibody perspective, RAS mutations regulate induction of a certain membrane protein, our undisclosed target. Pan RAS mutations and overexpression of our undisclosed target are found to be highly correlated in various RAS-driven tumors. As such, NN3206 is designed to demonstrate superb RAS subtype- or mutation-agnostic pharmacological activities.

Learn More

Details: Fully human IgG1 monoclonal antibody discovered by Novelty Nobility

Science: cKIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. cKIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. In inflammatory diseases, such as chronic urticaria, mast cell activation plays a central role in the onset and progression of the disease. Our anti-cKIT antibody specifically binds cKIT with high specificity and potently inhibits its activity.

Publications: 1. [Mol. Cell. Biochem] A fully human anti‑c‑Kit monoclonal antibody 2G4 inhibits proliferation and degranulation of human mast cells (2022)